Lv6
3125 积分 2020-08-11 加入
Current Therapy of the Patients with MDS: Walking towards Personalized Therapy
2个月前
已关闭
Role of Luspatercept in the Management of Lower-Risk Myelodysplastic Syndromes
2个月前
已完结
Novel Approaches and Future Directions in Myelodysplastic Syndrome Treatment
2个月前
已完结
Next-generation therapy for lower-risk MDS
2个月前
已关闭
Next-generation therapy for lower-risk MDS
2个月前
已关闭
Treatment patterns and outcomes with luspatercept in patients with lower‐risk myelodysplastic syndromes: A retrospective US cohort analysis
2个月前
已完结
Correction to: Treatment of Myelodysplastic Syndromes for Older Patients: Current State of Science, Challenges, and Opportunities
2个月前
已完结
Treatment of Myelodysplastic Syndromes for Older Patients: Current State of Science, Challenges, and Opportunities
2个月前
已完结
Luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): primary analysis of a phase 3, open-label, randomised, controlled trial
2个月前
已完结
Cost-of-Illness Studies: a guide to critical evaluation
3个月前
已完结
皖公网安备34019202002308
